Zydus Cadila gets USFDA nod to market Fingolimod capsules, Verapamil Hydrochloride Injection

Zydus Cadila has received final approval from the United States Food
and Drug Administration (USFDA) to market Fingolimod capsules,
(Gilenya) in the strengths of 0.5 mg, Zydus Cadila, part of Cadila
Healthcare group, said in a regulatory filing.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-cadila-gets-usfda-nod-to-market-fingolimod-capsules-verapamil-hydrochloride-injection/articleshow/78716968.cms

Comments

Post a Comment

Popular posts from this blog

NISER PhD Program Admission 2020-21 (Winter Session)

NISER PhD Admission 2020-2021 (Winter Session) – Apply Online NISER PhD Admission 2020-2021 (Winter Session) – Apply Online. Interested applicants can check details on the eligibility criteria, courses offered, application procedure, research areas, contact details and application link all given below: This call expires in :   NATIONAL INSTITUTE OF SCIENCE EDUCATION AND RESEARCH BHUBANESWAR […] The post NISER PhD Program Admission 2020-21 (Winter Session) appeared first on BioTecNika . https://www.biotecnika.org/2020/10/niser-phd-admission-2020-2021-winter-session-apply-online/ Biotech Admissions,Featured,M.Sc
Read more

Data Analyst Jobs – Life Sciences Apply at Cognizant

Data Analyst Jobs – Cognizant Life Sciences Apply Online Data Analyst Jobs – Cognizant Life Sciences Apply Online. Indian Nationals who are from a background in life sciences can apply for the Data Analyst vacancy that has been detailed below. Graduate/Postgraduate and Doctorate candidates are eligible. Interested and eligible candidates check out all of the […] The post Data Analyst Jobs – Life Sciences Apply at Cognizant appeared first on BioTecNika . https://www.biotecnika.org/2019/11/data-analyst-jobs-cognizant-life-sciences-apply-online/ B.Sc,B.Tech,Featured,Jobs,Life Sciences Jobs,M.Sc,M.Tech,Ph.D
Read more

Are hospitals prescribing the more expensive remdesivir instead of cheaper alternatives?

The DoP has asked the health ministry and drug regulatory authority to monitor if hospitals are prescribing the high-priced remdesivir where low-priced antibiotics would do, as it has received complaints of indiscriminate prescription of remdesivir by big hospitals, even in cases where it was not needed. https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/are-hospitals-prescribing-the-more-expensive-remdesivir-instead-of-cheaper-alternatives/articleshow/77135780.cms
Read more